Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Discovering the miR-26a/targetome in prostate cancer cells

ABSTRACT: In this work, we showed that the re-expression of miR-26a in DU-145 prostate cancer cells restored the tumor suppressor activity of miR-26a. To discover the genes and pathways elicited by miR-26a re-expression, we used the miRNA pull out assay to capture and the Next Generation Sequencing to identify the miR-26a targets. Data showed that: i) miR-26a captured both non-coding and coding RNAs; ii) 46% of transcripts were putative miR-26a targets according to target prediction algorithms; iii) 21 pathways were significantly enriched and the “Pathway in Cancer” was among those comprising the largest number of genes, including BIRC5 that we experimentally validated. Accordingly, the detection of cell proliferation-related events showed that miR-26a exerted its tumor suppressor activity at several levels, by decreasing the survival, impairing the migration of tumor cells and by inducing both apoptosis and cell cycle block. In conclusion, we showed that the collection of miR-26a interacting transcripts (miR-26a/targetome) represented a fruitful platform to decipher the miR-26a-dependent gene expression networks. In perspective the availability of miRNA-specific and tumor-specific targetomes will allow the discovery of new druggable tumor genes and pathways.

ORGANISM(S): Homo sapiens

PROVIDER: GSE85306 | GEO | 2017/04/04

SECONDARY ACCESSION(S): PRJNA338150

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Mouse Articular chondrocyte LC-MSMS of wild-type, miR-26a -/- and cartilage-specific miR-23ab clusters knockout mice

Project description:To reveal the potential regulation target genes of miR-26a and miR-23a/b clusters in articular chondrocytes, we performed a multi-omics analysis of LC-MSMS and RNA-seq using cultured chondrocytes samples, which were primarily isolated from 3-week-old wild-type, miR-26a -/- (with or without miR-26a mimic transfection afterwards) or miR-23a/b cluster flox/flox;Col2a1-cre mice. For LC-MSMS, protein from TRIZOL reagent was extracted, nanoLC-MSMS was performed. An expression list was made to further explore the regulation targets of miR-26a and miR-23a/b clusters.

2023-01-25 | PXD031868 | Pride

Transcription profiling by array of hMADS cells transfected with miR-26a

Project description:Human multipotent adipose-derived stem (hMADS) cells were transfected at confluence with miR-26a or miR-C (non-targeting control microRNA) and cells were harvested two days later (=d0) to identify mRNAs that are downregulated by miR-26a versus miR-C, as such mRNAs could be direct miR-26a targets.

2013-11-25 | E-MARS-28 | biostudies-arrayexpress

MYC stimulates EZH2 expression by repression of its negative regulator miR-26a

Project description:The MYC oncogene, which is commonly mutated/amplified in tumors, represents an important regulator of cell growth owing to its ability to induce both proliferation and apoptosis. Recent evidence links MYC to altered miRNA expression, thereby suggesting that MYC-regulated miRNAs might contribute to tumorigenesis. To further analyze the impact of MYC-regulated miRNAs we investigated a murine lymphoma model harboring the MYC transgene in a Tet-off system in order to control its expression. Microarray-based miRNA expression profiling revealed both known and novel MYC targets. Among the miRNAs repressed by MYC we identified the potential tumor suppressor miR-26a, which possessed the ability to attenuate proliferation in MYC-dependent cells. Interestingly, miR-26a was also found to be deregulated in primary human Burkitt lymphoma samples, thereby likely being of clinical relevance. While today only few miRNA targets have been identified in human disease, we could show that ectopic expression of miR-26a influenced cell cycle progression by targeting the bona fide oncogene EZH2, a Polycomb protein and global regulator of gene expression yet unknown to be regulated by miRNAs. Thus, in addition to directly targeting protein-coding genes, MYC modulates genes important to oncogenesis via deregulation of miRNAs, thereby vitally contributing to MYC-induced lymphomagenesis.

2008-07-31 | GSE12278 | GEO

Effects of miR-26a expression and miRNA-sponge-mediated miR-26 family knockdown on the transcriptome of B cell precursors

Project description:Here, we have screened a miRNA expression library in a pre-B cell expression system to identify miRNAs with a potential oncogenic activity in early lymphocytes. We show that miR-26a is sufficient to transform B cell precursors in vitro as defined by growth factor independence, and demonstrate that its continuous expression is necessary to keep cells in the transformed state. Mechanistically, we find that expression of miR-26a protects against apoptosis induced by growth factor withdrawal as well as DNA damage, provides a competitve advantage and interferes with the differentiation of pre-B to immature B cells. In consequence, transformed cells express the pre-BCR on the cell surface, which appears to provide signals for ongoing proliferation and survival. Using microarray analysis, we identified several previously known and novel putative target genes of miR-26a in B cell precursors. A key target appears to be PTEN, a well established tumor suppressor and regulator of PI3K signaling, as knockdown of Pten mRNA by shRNA at least partially phenocopies miR-26a overexpression. To gain inside into the physiological role of miR-26 in early B cell develobment, in contrast to the oncogenic situation if aberrantly overexpressed, we further more sequestered endogenous miR-26a and b by expression of a miRNA sponge. This functional knockdown indeed induced the reciprocal phenotype relative to the overexpression, i.e. cells had a proliferative disadvantage and differentiated more efficient into immature B cells. Surprisingly, however, transcriptional changes induced by miR-26 sequestration were very mild. We therefoer hypothesize that most of the sponge-mediated deregulation is below detection level while still being functional relevant.

2022-01-01 | GSE186236 | GEO

MiR-26a targets EphA2 to resist intracellular Listeria monocytogenes in macrophages

Project description:We performed transcriptome analyses of miR-26a-overexpressing RAW264.7 cells (RAW264.7.miR-26a.OE) and NC-plasmid-transfected RAW264.7 cells (RAW264.7.NC), using RNA-seq . We identified 121 genes that were downregulated in RAW264.7.miR-26a.OE cells compared with RAW264.7.NC cells. Among the downregulated genes, we identified four putative target genes, using TargetScan (www.targetscan.org), including EphA2, Map3k9, Nhsl1, and Otud1, which all contain a putative miR-26a seed sequence.

2022-06-01 | GSE149842 | GEO

miR-26a regulate the extracellular vesicle secretion from prostate cancer cells via targeting PFDN4, CHORDC1 and SHC4

Project description:Extracellular vesicles (EVs) are known to be involved in inter-cellular communication during cancer progression, however, the biogenesis of EVs in cancer cells is not completely unveiled. It has been shown that microRNAs (miRNAs) regulated variety of physiological and pathological phenomena, thus, miRNAs could regulate the EV secretion. Here, we have performed high throughput miRNA-based screening to identify the regulators of EV secretion using ExoScreen assay. By this miRNA-based screening, we identified miR-26a, which was reported as tumor suppressive miRNA, was found to be an miRNA involved in EV secretion from prostate cancer (PCa) cells. To study the effect of miR-26a on gene expression in EV secretion, transcriptome analysis for miR-26a overexpressing PCa cell lines was performed.

2020-05-12 | GSE132161 | GEO

Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells

Project description:Objective: Trastuzumab has been used for the treatment of HER2-positive breast cancer (BC). However, a subset of BC patients exhibited resistance to trastuzumab therapy. Thus, clarifying the molecular mechanism of trastuzumab treatment will be beneficial to improve the treatment of HER2-positive BC patients. In this study, we identified trastuzumab-responsive microRNAs that are involved in the therapeutic effects of trastuzumab. Methods and results: RNA samples were obtained from HER2-positive (SKBR3 and BT474) and HER2-negetive (MCF7 and MDA-MB-231) cells with and without trastuzumab treatment for 6 days. Next, we conducted a microRNA profiling analysis using these samples to screen those microRNAs that were up- or downregulated only in HER2-positive cells. This analysis identified miR-26a and miR-30b as trastuzumab-inducible microRNAs. Transfecting miR-26a and miR-30b induced cell growth suppression in the BC cells by 40% and 32%, respectively. A cell cycle analysis showed that these microRNAs induced G1 arrest in HER2-positive BC cells as trastuzumab did. An Annexin-V assay revealed that miR-26a but not miR-30b induced apoptosis in HER2-positive BC cells. Using the prediction algorithms for microRNA targets, we identified cyclin E2 (CCNE2) as a target gene of miR-30b. A luciferase-based reporter assay demonstrated that miR-30b post-transcriptionally reduced 27% (p=0.005) of the gene expression by interacting with two binding sites in the 3’-UTR of CCNE2. Conclusion: In BC cells, trastuzumab modulated the expression of a subset of microRNAs, including miR-26a and miR-30b. The upregulation of miR-30b by trastuzumab may play a biological role in trastuzumab-induced cell growth inhibition by targeting CCNE2. We obtained microRNA expression profiles of breast cancer cell lines, MCF7, MDA-MB-231, SKBR3, and BT474, with or without trastuzumab (4microgram/mL) treatment.

2012-06-02 | E-GEOD-38415 | biostudies-arrayexpress

Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells

2012-06-03 | GSE38415 | GEO

Transcription profiling by array of hMADS cells transfected with miR-26a and induced to differentiate into adipocytes

Project description:Human multipotent adipose-derived stem (hMADS) cells were transfected at confluence with miR-26a or miR-C (non-targeting control microRNA). Two days later (=d0), adipocyte differentiation was induced. At d9 after start of differentiation, cells were harvested to identify mRNAs that are down- and upregulated by miR-26a versus miR-C.

2013-11-25 | E-MARS-29 | biostudies-arrayexpress

RNA-sequencing (RNA-seq) in breast cancer cell lines after ectopic manipulation of miR-26a expression

Project description:RNA sequencing technology has been carried out in order to evaluate mRNA expression changes after manipulation of miR-26a in both MCF-7 and MDA-MB-231 breast cancer cell lines. To evaluate the entire set of genes modulated by miR-26a in breast cancer, we performed RNA-seq after ectopic manipulation of this miRNA. We over-expressed miR-26a in MCF-7 epithelial cancer cell lines and also reduced its activity by stably transfecting MDA-MB-231 mesenchymal-like cancer cell lines with a specific sponge vector. GO terms and pathway enriched analysis of the transcripts that significantly change upon miR-26 ectopic manipulation implicates miR-26ab in cell cycle, apoptosis, cell spreading and cell adhesion in breast cancer

2016-06-30 | E-GEOD-43726 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data